[go: up one dir, main page]

MX2019008109A - Combinacion de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmaceuticas de esta. - Google Patents

Combinacion de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmaceuticas de esta.

Info

Publication number
MX2019008109A
MX2019008109A MX2019008109A MX2019008109A MX2019008109A MX 2019008109 A MX2019008109 A MX 2019008109A MX 2019008109 A MX2019008109 A MX 2019008109A MX 2019008109 A MX2019008109 A MX 2019008109A MX 2019008109 A MX2019008109 A MX 2019008109A
Authority
MX
Mexico
Prior art keywords
mcl
inhibitor
combination
compound
taxan
Prior art date
Application number
MX2019008109A
Other languages
English (en)
Other versions
MX385115B (es
Inventor
Geneste Olivier
Porter Dale
HALILOVIC Ensar
Chanrion Maïa
Leticia Maragno Ana
Merino Delphine
Whittle James
VAILLANT François
Visvader Jane
Lindeman Geoffrey
Lessene Guillaume
MARANGONI Elisabetta
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Priority claimed from PCT/EP2018/050298 external-priority patent/WO2018127575A1/en
Publication of MX2019008109A publication Critical patent/MX2019008109A/es
Publication of MX385115B publication Critical patent/MX385115B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Una combinación que comprende un inhibidor de MCL-1 y un compuesto taxano, y composiciones y usos de ésta.
MX2019008109A 2017-01-06 2018-01-05 Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta. MX385115B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762443082P 2017-01-06 2017-01-06
EP17157779 2017-02-24
US201762527360P 2017-06-30 2017-06-30
PCT/EP2018/050298 WO2018127575A1 (en) 2017-01-06 2018-01-05 Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
MX2019008109A true MX2019008109A (es) 2019-09-04
MX385115B MX385115B (es) 2025-03-14

Family

ID=61007674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008109A MX385115B (es) 2017-01-06 2018-01-05 Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta.

Country Status (22)

Country Link
US (1) US10765680B2 (es)
EP (1) EP3565547B1 (es)
JP (1) JP7179733B2 (es)
KR (1) KR102576567B1 (es)
CN (1) CN110381937A (es)
AU (1) AU2018205735B2 (es)
BR (1) BR112019013907A2 (es)
CA (1) CA3049095C (es)
CL (1) CL2019001859A1 (es)
CO (1) CO2019007261A2 (es)
CU (1) CU20190064A7 (es)
ES (1) ES2975274T3 (es)
GE (1) GEP20227372B (es)
IL (1) IL267791B (es)
JO (1) JOP20190159B1 (es)
MA (1) MA47198A (es)
MX (1) MX385115B (es)
MY (1) MY202239A (es)
PH (1) PH12019501451A1 (es)
RU (1) RU2763544C2 (es)
UA (1) UA125142C2 (es)
ZA (1) ZA201904280B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202114682A (zh) * 2019-06-17 2021-04-16 法商施維雅藥廠 Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物
WO2024138096A2 (en) * 2022-12-22 2024-06-27 Biopurification, Llc Taxane formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100870314B1 (ko) * 2008-02-19 2008-11-25 고려대학교 산학협력단 암 치료용 핵산 의약 조성물
WO2012122370A2 (en) * 2011-03-08 2012-09-13 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105311016A (zh) * 2014-07-24 2016-02-10 中国科学院大连化学物理研究所 一种抗细胞凋亡Mcl-1蛋白抑制剂及其应用
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP6642734B2 (ja) * 2017-08-02 2020-02-12 株式会社村田製作所 アクチュエータ

Also Published As

Publication number Publication date
ES2975274T3 (es) 2024-07-04
KR102576567B1 (ko) 2023-09-07
KR20190103317A (ko) 2019-09-04
JP7179733B2 (ja) 2022-11-29
MX385115B (es) 2025-03-14
RU2019123982A3 (es) 2021-03-25
KR102576567B9 (ko) 2023-12-15
PH12019501451A1 (en) 2020-06-01
UA125142C2 (uk) 2022-01-19
EP3565547B1 (en) 2024-03-13
MA47198A (fr) 2019-11-13
RU2019123982A (ru) 2021-02-08
JOP20190159A1 (ar) 2019-06-25
US10765680B2 (en) 2020-09-08
MY202239A (en) 2024-04-18
AU2018205735B2 (en) 2024-02-01
US20190336505A1 (en) 2019-11-07
IL267791A (en) 2019-09-26
JP2020503361A (ja) 2020-01-30
BR112019013907A2 (pt) 2020-02-04
JOP20190159B1 (ar) 2023-09-17
AU2018205735A1 (en) 2019-07-11
RU2763544C2 (ru) 2021-12-30
GEP20227372B (en) 2022-04-25
CN110381937A (zh) 2019-10-25
CU20190064A7 (es) 2020-02-04
CL2019001859A1 (es) 2019-11-15
IL267791B (en) 2022-02-01
CA3049095C (en) 2022-01-25
CA3049095A1 (en) 2018-07-12
CO2019007261A2 (es) 2019-07-31
ZA201904280B (en) 2022-03-30
EP3565547A1 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
MX2019011496A (es) Composiciones de niraparib.
CL2016001131A1 (es) Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones.
UY36151A (es) ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
CL2019003037A1 (es) Combinaciones fungicidas.
MX374654B (es) Compuestos útiles para inhibir ror-gamma-t.
CL2018001157A1 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
AR112217A1 (es) Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
ECSP19006687A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl-1, usos y composiciones farmacéuticas de éstos
CO2019007261A2 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CL2018000489A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
CY1124258T1 (el) ΕΝΩΣΕΙΣ ΧΡΗΣΙΜΕΣ ΓΙΑ ΑΝΑΣΤΟΛΗ ROR-γ-t
CU20170134A7 (es) 2-tiopirimidinonas
NO20161136A1 (en) Compounds and compositions for biofilm prevention
EA201991623A1 (ru) Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции
EA201990305A1 (ru) Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
HK40017059A (en) Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
BR112016022439A2 (pt) Composições farmacêuticas que compreendem cefepima ou sulbactama
AR111177A1 (es) Composiciones farmacéuticas que comprenden un inhibidor de jak